$2.36
0.85%
Downside
Day's Volatility :2.9%
Upside
2.07%
20.34%
Downside
52 Weeks Volatility :70.21%
Upside
62.6%
Period | Akoya Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 15.12% | 5.1% | 0.0% |
6 Months | -50.42% | 4.9% | 0.0% |
1 Year | -48.02% | 16.6% | 0.0% |
3 Years | -83.59% | 13.2% | -22.3% |
Market Capitalization | 116.8M |
Book Value | $0.45 |
Earnings Per Share (EPS) | -1.17 |
Wall Street Target Price | 5.0 |
Profit Margin | -64.74% |
Operating Margin TTM | -47.47% |
Return On Assets TTM | -18.09% |
Return On Equity TTM | -128.2% |
Revenue TTM | 93.2M |
Revenue Per Share TTM | 1.89 |
Quarterly Revenue Growth YOY | -1.5% |
Gross Profit TTM | 43.4M |
EBITDA | -39.5M |
Diluted Eps TTM | -1.17 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.02 |
EPS Estimate Next Year | -0.54 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.19 |
What analysts predicted
Upside of 111.86%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 42.2M | - |
Net Income | -14.8M | - |
Net Profit Margin | -34.93% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 42.4M | ↑ 0.49% |
Net Income | -16.7M | ↑ 13.25% |
Net Profit Margin | -39.36% | ↓ 4.43% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 54.9M | ↑ 29.39% |
Net Income | -42.9M | ↑ 157.0% |
Net Profit Margin | -78.18% | ↓ 38.82% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 74.9M | ↑ 36.31% |
Net Income | -70.6M | ↑ 64.53% |
Net Profit Margin | -94.37% | ↓ 16.19% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 96.6M | ↑ 29.09% |
Net Income | -63.3M | ↓ 10.36% |
Net Profit Margin | -65.53% | ↑ 28.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.4M | ↑ 0.9% |
Net Income | -18.8M | ↓ 0.39% |
Net Profit Margin | -87.82% | ↑ 1.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.5M | ↑ 9.86% |
Net Income | -20.8M | ↑ 10.64% |
Net Profit Margin | -88.44% | ↓ 0.62% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.2M | ↑ 7.2% |
Net Income | -12.9M | ↓ 37.91% |
Net Profit Margin | -51.22% | ↑ 37.22% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 26.5M | ↑ 5.04% |
Net Income | -10.8M | ↓ 16.37% |
Net Profit Margin | -40.78% | ↑ 10.44% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 18.4M | ↓ 30.72% |
Net Income | -23.5M | ↑ 117.4% |
Net Profit Margin | -127.98% | ↓ 87.2% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 23.2M | ↑ 26.23% |
Net Income | -13.1M | ↓ 44.01% |
Net Profit Margin | -56.76% | ↑ 71.22% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 89.4M | - |
Total Liabilities | 119.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 77.7M | ↓ 13.14% |
Total Liabilities | 59.1M | ↓ 50.58% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 190.9M | ↑ 145.82% |
Total Liabilities | 69.6M | ↑ 17.71% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 176.0M | ↓ 7.79% |
Total Liabilities | 117.5M | ↑ 68.86% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 180.4M | ↑ 2.46% |
Total Liabilities | 126.6M | ↑ 7.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 154.3M | ↓ 12.35% |
Total Liabilities | 112.2M | ↓ 4.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 188.9M | ↑ 22.41% |
Total Liabilities | 117.0M | ↑ 4.28% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 177.2M | ↓ 6.16% |
Total Liabilities | 115.3M | ↓ 1.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 180.4M | ↑ 1.76% |
Total Liabilities | 126.6M | ↑ 9.83% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 154.8M | ↓ 14.2% |
Total Liabilities | 122.0M | ↓ 3.61% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 143.7M | ↓ 7.11% |
Total Liabilities | 121.5M | ↓ 0.44% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.8M | - |
Investing Cash Flow | -12.9M | - |
Financing Cash Flow | 28.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.8M | ↓ 50.33% |
Investing Cash Flow | 6.7M | ↓ 152.19% |
Financing Cash Flow | 5.5M | ↓ 80.79% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -36.1M | ↑ 427.08% |
Investing Cash Flow | -5.1M | ↓ 175.71% |
Financing Cash Flow | 137.0M | ↑ 2397.9% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -53.5M | ↑ 48.32% |
Investing Cash Flow | -14.1M | ↑ 176.38% |
Financing Cash Flow | 28.7M | ↓ 79.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.8M | ↑ 97.44% |
Investing Cash Flow | 6.2M | ↓ 72.0% |
Financing Cash Flow | -419.0K | ↓ 104.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.8M | ↓ 40.26% |
Investing Cash Flow | -1.4M | ↓ 122.97% |
Financing Cash Flow | 46.3M | ↓ 11156.56% |
Sell
Neutral
Buy
Akoya Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Akoya Biosciences Inc | 20.41% | -50.42% | -48.02% | -83.59% | -90.94% |
![]() Intuitive Surgical, Inc. | 5.02% | 20.15% | 58.74% | 31.28% | 184.98% |
![]() Resmed Inc. | 16.09% | 27.14% | 62.7% | -17.28% | 81.24% |
![]() Becton, Dickinson And Company | 0.02% | -2.08% | -12.88% | -9.76% | -9.75% |
![]() West Pharmaceutical Services Inc | 1.18% | -17.93% | -26.4% | -35.64% | 104.36% |
![]() Alcon Ag | 3.83% | 8.9% | 15.02% | 11.44% | 61.54% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Akoya Biosciences Inc | NA | NA | NA | -1.02 | -1.28 | -0.18 | NA | 0.45 |
![]() Intuitive Surgical, Inc. | 81.91 | 81.91 | 4.06 | 6.65 | 0.16 | 0.08 | NA | 41.4 |
![]() Resmed Inc. | 35.33 | 35.33 | 2.05 | 7.71 | 0.23 | 0.13 | 0.01 | 33.11 |
![]() Becton, Dickinson And Company | 46.72 | 46.72 | 1.08 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
![]() West Pharmaceutical Services Inc | 42.71 | 42.71 | 5.15 | 6.51 | 0.2 | 0.11 | 0.0 | 35.49 |
![]() Alcon Ag | 42.64 | 42.64 | 3.53 | 3.05 | 0.05 | 0.03 | 0.0 | 42.35 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Akoya Biosciences Inc | Buy | $116.8M | -90.94% | NA | -64.74% |
![]() Intuitive Surgical, Inc. | Buy | $169.4B | 184.98% | 81.91 | 27.65% |
![]() Resmed Inc. | Buy | $36.0B | 81.24% | 35.33 | 21.79% |
![]() Becton, Dickinson And Company | Buy | $67.4B | -9.75% | 46.72 | 7.13% |
![]() West Pharmaceutical Services Inc | Buy | $21.8B | 104.36% | 42.71 | 18.25% |
![]() Alcon Ag | Buy | $46.7B | 61.54% | 42.64 | 11.44% |
Insights on Akoya Biosciences Inc
Revenue is up for the last 2 quarters, 18.35M → 23.16M (in $), with an average increase of 20.8% per quarter
Netprofit is up for the last 2 quarters, -23.48M → -13.14M (in $), with an average increase of 78.6% per quarter
In the last 1 year, Resmed Inc. has given 62.7% return, outperforming this stock by 110.7%
In the last 3 years, Akoya Biosciences Inc has experienced a drawdown of -83.6%, however Intuitive Surgical, Inc. resisted the overall trend and outperformed by 66.3%
Blue Water Life Science Advisors, LLC
BlackRock Inc
Vanguard Group Inc
Geode Capital Management, LLC
State Street Corporation
Parkman Healthcare Partners LLC
akoya biosciences is developing a novel high-parameter tissue analysis platform, at an order of magnitude beyond what is currently possible. our codex (tm) (co-detection by indexing) system enables deep proteomic profiling...all on your existing microscope. if you are a scientist or software engineer interested in revolutionizing the science of imaging, then akoya is the place for you. contact is at info@akoyabio.com.
Organization | Akoya Biosciences Inc |
Employees | 330 |
CEO | Mr. Brian McKelligon |
Industry | Healthcare |